Letrozole Bodybuilding Anabolic Steroid Hormones for Cancer Treatment CAS 112809-51-5 Femara

 
Letrozole Bodybuilding Anabolic Steroid Hormones for Cancer Treatment CAS 112809-51-5 Femara
 
Quick Detail:
 
Letrozole (trade name Femara) is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery.
Alias: Femara, Letrozole, TROZET
CAS :112809-51-5
MF: C17H11N5
MW: 285.3
Character: White crystalline powder.
Manufacturer : Yuanyang
Other drugs in same class:Anastrozole,Letrozole,Tamoxifen citrate,Exemestane
Usage: Letrozole is a powerful Aromatase Inhibitor that was developed to fight breast cancer. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia. It will also raise testosterone levels because of the lowered estrogen in the body. Side effects from Letrozole include a lowered sex drive and continuous use can lead to lowered lipid function and an impaired immune system.
 
Description:
 
1). Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.
 
2). Letrozole has been used for ovarian stimulation by fertility doctors since 2001 because it has fewer side-effects than clomiphene (Clomid) and less chance of multiple gestation. A Canadian study presented at the American Society of Reproductive Medicine 2005 Conference suggested that letrozole may increase the risk of birth defects. A more detailed ovulation induction follow-up study found that letrozole, compared with a control group of clomiphene, had significantly lower congenital malformations and chromosomal abnormalities at an overall rate of 2.4% (1.2% major malformations) compared with clomiphene 4.8% (3.0% major malformations). Despite this, India banned the usage of letrozole in 2011, citing potential risks to infants.
 
Applications:
 
1). Femara (letrozole) is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years. It is a non-steroidal aromatase inhibitor (lowers estrogen production). This medication is available in generic form.
 
2). The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals. Other drugs may interact with Femara. Tell your doctor all prescription and over-the-counter medications and supplements you use. Femara must not be used during pregnancy. It may harm a fetus. Femara is used mainly in women after menopause. If you have recently gone through menopause, discuss birth control with your doctor. Do not use birth control containing estrogen. It is unknown if this drug passes into breast milk and may harm a nursing infant. Breast-feeding while using this drug is not recommended. 
 
Specifications:

 

Product name	Letrozole
Other name	Femara, Letrozole, TROZET
CAS register number	112809-51-5
Molecular formula	C17H11N5
Molecular weight	285.3
Molecular structure
Assay	98%
Appearance	White crystalline powder
Package	1kg/aluminium foil bag or as required
Usage	can be used as pharmaceutical material
Minimum order quantity	10g
Shipping	By express courier
Shipping leading time	Within 12 hours after receiving the payment
Payment options	Western Union, MoneyGram, T/T
Price	Negotiated